TY - JOUR
T1 - Recommendations for tilt table testing and other provocative cardiovascular autonomic tests in conditions that may cause transient loss of consciousness
T2 - Consensus statement of the European Federation of Autonomic Societies (EFAS) endorsed by the American Autonomic Society (AAS) and the European Academy of Neurology (EAN)
AU - Thijs, Roland D
AU - Brignole, Michele
AU - Falup-Pecurariu, Cristian
AU - Fanciulli, Alessandra
AU - Freeman, Roy
AU - Guaraldi, Pietro
AU - Jordan, Jens
AU - Habek, Mario
AU - Hilz, Max
AU - Pavy-LeTraon, Anne
AU - Stankovic, Iva
AU - Struhal, Walter
AU - Sutton, Richard
AU - Wenning, Gregor
AU - van Dijk, J Gert
N1 - Funding Information:
Dr. Thijs reports personal fees from Medtronic, Union Chimique Belge (UCB), Glaxo Smith Kline (GSK), Theravarance, Novartis and grants from Dutch National Epilepsy Fund, Christelijke Vereniging voor de Verpleging van Lijders aan Epilepsie, AC Thomson Foundation, Medtronic, The Netherlands Organisation for Health Research and Development (843002707), outside the submitted work. Dr. Fanciulli reports royalties from Springer Nature Publishing Group and Thieme Verlag, speaker fees from the Austrian Autonomic Society, Austrian Neurology Society, Austrian Parkinson Society, Ordensklinikum Linz, International Parkinson's disease and Movement Disorders Society and Theravance Biopharma, research grants from the Stichting ParkinsonFond, MSA Coalition and the Österreichischer Austausch Dienst, outside of the submitted work. Prof Sutton serves as consultant to Medtronic Inc., is a member of Speakers Bureau SJM Abbott Laboratories, and shareholder in Edwards Lifesciences and Boston Scientific Corp, outside of the submitted work. Prof Pavy-Le Traon reports research grant from the French Ministry of Health, outside de submitted work, outside of the submitted work. Prof Jordan served as advisor for Novo-Nordisk, Bayer, received research support from Boston-Scientific and Boehringer Ingelheim and is cofounder of Eternygen GmbH, outside the submitted work. Prof. Habek participated as clinical investigator, speaker and/or advisor for Biogen, Sanofi Genzyme, Merck, Bayer, Novartis, Pliva/Teva, Roche, Alvogen, Actelion, Alexion Pharmaceuticals, outside the submitted work. Prof Struhal reports consultancy for Boehringer, Eli Lilly, royalties from Manz-Rechtsverlag, Springer, Oxford University Press, speaker fees from Boehringer, Merz, Medconvent, Donau-Universität Krems, Austrian Society of Neurology, Manz-Rechtsverlag. Prof. Hilz received consulting honoraria from Alnylam and Sanofi-Genzyme, lecturing honoraria and travel support from Bayer Health Care, Amicus, Sanofi-Genzyme, and research funding from Novartis Pharma and Bayer Health Care.
Funding Information:
Dr. Thijs reports personal fees from Medtronic, Union Chimique Belge (UCB), Glaxo Smith Kline (GSK), Theravarance, Novartis and grants from Dutch National Epilepsy Fund, Christelijke Vereniging voor de Verpleging van Lijders aan Epilepsie, AC Thomson Foundation, Medtronic, The Netherlands Organisation for Health Research and Development (843002707), outside the submitted work. Dr. Fanciulli reports royalties from Springer Nature Publishing Group and Thieme Verlag, speaker fees from the Austrian Autonomic Society, Austrian Neurology Society, Austrian Parkinson Society, Ordensklinikum Linz, International Parkinson's disease and Movement Disorders Society and Theravance Biopharma, research grants from the Stichting ParkinsonFond, MSA Coalition and the Österreichischer Austausch Dienst, outside of the submitted work. Prof Sutton serves as consultant to Medtronic Inc., is a member of Speakers Bureau SJM Abbott Laboratories, and shareholder in Edwards Lifesciences and Boston Scientific Corp, outside of the submitted work. Prof Pavy-Le Traon reports research grant from the French Ministry of Health, outside de submitted work, outside of the submitted work. Prof Jordan served as advisor for Novo-Nordisk, Bayer, received research support from Boston-Scientific and Boehringer Ingelheim and is cofounder of Eternygen GmbH, outside the submitted work. Prof. Habek participated as clinical investigator, speaker and/or advisor for Biogen, Sanofi Genzyme, Merck, Bayer, Novartis, Pliva/Teva, Roche, Alvogen, Actelion, Alexion Pharmaceuticals, outside the submitted work. Prof Struhal reports consultancy for Boehringer, Eli Lilly, royalties from Manz-Rechtsverlag, Springer, Oxford University Press, speaker fees from Boehringer, Merz, Medconvent, Donau-Universität Krems, Austrian Society of Neurology, Manz-Rechtsverlag. Prof. Hilz received consulting honoraria from Alnylam and Sanofi-Genzyme, lecturing honoraria and travel support from Bayer Health Care, Amicus, Sanofi-Genzyme, and research funding from Novartis Pharma and Bayer Health Care .
Publisher Copyright:
© 2021 The Authors
PY - 2021/7
Y1 - 2021/7
N2 - An expert committee was formed to reach consensus on the use of Tilt Table Testing (TTT) in the diagnosis of disorders that may cause transient loss of consciousness (TLOC) and to outline when other provocative cardiovascular autonomic tests are needed. While TTT adds to history taking, it cannot be a substitute for it. An abnormal TTT result is most meaningful if the provoked event is recognised by patients or eyewitnesses as similar to spontaneous ones. The minimum requirements to perform TTT are a tilt table, a continuous beat-to-beat blood pressure monitor, at least one ECG lead, protocols for the indications stated below and trained staff. This basic equipment lends itself to perform (1) additional provocation tests, such as the active standing test carotid sinus massage and autonomic function tests; (2) additional measurements, such as video, EEG, transcranial Doppler, NIRS, end-tidal CO2 or neuro-endocrine tests; (3) tailor-made provocation procedures in those with a specific and consistent trigger of TLOC. TTT and other provocative cardiovascular autonomic tests are indicated if the initial evaluation does not yield a definite or highly likely diagnosis, but raises a suspicion of (1) reflex syncope, (2) the three forms of orthostatic hypotension (OH), i.e. initial, classic and delayed OH, as well as delayed orthostatic blood pressure recovery, (3) postural orthostatic tachycardia syndrome or (4) psychogenic pseudosyncope. A therapeutic indication for TTT is to teach patients with reflex syncope and OH to recognise hypotensive symptoms and to perform physical counter manoeuvres.
AB - An expert committee was formed to reach consensus on the use of Tilt Table Testing (TTT) in the diagnosis of disorders that may cause transient loss of consciousness (TLOC) and to outline when other provocative cardiovascular autonomic tests are needed. While TTT adds to history taking, it cannot be a substitute for it. An abnormal TTT result is most meaningful if the provoked event is recognised by patients or eyewitnesses as similar to spontaneous ones. The minimum requirements to perform TTT are a tilt table, a continuous beat-to-beat blood pressure monitor, at least one ECG lead, protocols for the indications stated below and trained staff. This basic equipment lends itself to perform (1) additional provocation tests, such as the active standing test carotid sinus massage and autonomic function tests; (2) additional measurements, such as video, EEG, transcranial Doppler, NIRS, end-tidal CO2 or neuro-endocrine tests; (3) tailor-made provocation procedures in those with a specific and consistent trigger of TLOC. TTT and other provocative cardiovascular autonomic tests are indicated if the initial evaluation does not yield a definite or highly likely diagnosis, but raises a suspicion of (1) reflex syncope, (2) the three forms of orthostatic hypotension (OH), i.e. initial, classic and delayed OH, as well as delayed orthostatic blood pressure recovery, (3) postural orthostatic tachycardia syndrome or (4) psychogenic pseudosyncope. A therapeutic indication for TTT is to teach patients with reflex syncope and OH to recognise hypotensive symptoms and to perform physical counter manoeuvres.
KW - Consensus
KW - Humans
KW - Neurology
KW - Postural Orthostatic Tachycardia Syndrome
KW - Tilt-Table Test
KW - Unconsciousness
KW - United States
UR - http://www.scopus.com/inward/record.url?scp=85106965562&partnerID=8YFLogxK
U2 - 10.1016/j.autneu.2021.102792
DO - 10.1016/j.autneu.2021.102792
M3 - Journal article
C2 - 33752997
SN - 1566-0702
VL - 233
SP - 102792
JO - Autonomic Neuroscience: Basic and Clinical
JF - Autonomic Neuroscience: Basic and Clinical
M1 - 102792
ER -